Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS-201 Combined With Lenvatinib in SCLC
NCT04951947Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in small cell lung cancer (SCLC), sponsored by Hunan Cancer Hospital. Primary endpoint: Objective Response Rate at 1 year. Started Jun 2023; status: recruiting.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04951947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951947.